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therapy for patients with T2DM: an 18-month
prospective interventional study
Nasser M Al-Daghri1,2,3*, Khalid M Alkharfy1,2,4, Abdulaziz Al-Othman5, Emad El-Kholie1, Osama Moharram6,
Majed S Alokail1,2,3, Yousef Al-Saleh3,7, Shaun Sabico1,3, Sudhesh Kumar8 and George P Chrousos1,9Abstract
Background: Vitamin D deficiency has been associated with impaired human insulin action, suggesting a role in
the pathogenesis of diabetes mellitus type 2 (T2DM). In this prospective interventional study we investigated the
effects of vitamin D3 supplementation on the metabolic profiles of Saudi T2DM subjects pre- and post-vitamin D
supplementation over an 18-month period.
Methods: T2DM Saudi subjects (men, N = 34: Age: 56.6 ± 8.7 yr, BMI, 29.1 ± 3.3 kg/m2; women, N = 58: Age:
51.2 ± 10.6 yr, BMI 34.3 ± 4.9 kg/m2;) were recruited and given 2000 IU vitamin D3 daily for 18 months.
Anthropometrics and fasting blood were collected (0, 6, 12, 18 months) to monitor serum 25-hydroxyvitamin D
using specific ELISA, and to determine metabolic profiles by standard methods.
Results: In all subjects there was a significant increase in mean 25-hydroxyvitamin D levels from baseline
(32.2 ± 1.5 nmol/L) to 18 months (54.7 ± 1.5 nmol/L; p< 0.001), as well as serum calcium (baseline = 2.3 ± 0.23 mmol/L
vs. 18 months = 2.6 ± 0.1 mmol/L; p= 0.003). A significant decrease in LDL- (baseline = 4.4 ± 0.8 mmol/L vs.
18 months = 3.6 ± 0.8 mmol/L, p< 0.001] and total cholesterol (baseline = 5.4 ± 0.2 mmol/L vs.
18 months = 4.9 ± 0.3 mmol/L, p< 0.001) were noted, as well as a significant improvement in HOMA-β function
(p= 0.002). Majority of the improvements elicited were more prominent in women than men.
Conclusion: In the Saudi T2DM population receiving oral Vitamin D3 supplementation (2000 IU/day), circulating
25-hydroxyvitamin D levels remained below normal 18 months after the onset of treatment. Yet, this “suboptimal”
supplementation significantly improved lipid profile with a favorable change in HDL/LDL ratio, and HOMA-β
function, which were more pronounced in T2DM females.
Keywords: Vitamin D, Diabetes mellitus, Saudi, SupplementationBackground
In recent years, vitamin D deficiency has gained unpre-
cedented attention in the fields of preventive cardiology
and endocrinology, primarily because of the extra-
skeletal pleiotropic effects of this hormone, and the as-
sociation of its deficit with insulin resistance, diabetes
mellitus and an increased cardiovascular risk [1-3]. A
unifying factor that links diabetes mellitus types 1 and* Correspondence: aldaghri2011@gmail.com
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reproduction in any medium, provided the or2 (T1DM and T2DM, respectively) is the expression of
vitamin D receptors (VDRs) in more than 30 biological
tissues, including the pancreatic islet cells [3-5]. On
the other hand, it is common for patients with T1DM
and T2DM to have vitamin D deficiency [6]. Further-
more, several longitudinal and observational studies
have demonstrated that low levels of serum 25-
hydroxyvitamin D predict T2DM risk in Europeans
[7,8], African-Americans [9], South Asians [10] and na-
tive American children [11]. Vitamin D correction,
therefore, may increase insulin secretion and improve
glucose homeostasis; however, its effects on healthy
individuals or in those with impaired glucose tolerance
remain unclear [6].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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min D deficiency is startlingly high as compared to
other geographical regions [12]. Specifically, in the king-
dom of Saudi Arabia (KSA), where the intensity of sun-
light is paradoxically directly proportional to the
prevalence of vitamin D deficiency [13], hypovitamino-
sis D has been implicated not only as a significant pre-
dictor of osteoporosis among apparently healthy men
and post-menopausal women [14,15], but also signifi-
cantly associated to cardiometabolic risk factors in both
children and adults [16,17]. Interestingly, there is an
equally alarming prevalence of chronic non-communicable
diseases in KSA, including T2DM, obesity, the metabolic
syndrome, and cardiovascular diseases [18].
Previously we demonstrated a modest reversal of
metabolic syndrome manifestations among a cohort of
adult Saudis who were advised vitamin D correction
through increased sun exposure and dietary vitamin D
intake [19]. In the current interventional study, we
aimed to determine the metabolic effects of oral vitamin
D supplementation in a cohort of T2DM Saudi subjects
over time. This study may shed light as to whether oral
vitamin D supplementation can be an adjunct therapy in
T2DM Saudi patients, and on the importance of opti-
mizing vitamin D levels in the prevention and improved
management of chronic non-communicable diseases
such as T2DM.
Methods
Site and duration of the study
This is a multi-center, interventional study conducted at
the primary health care out -patient clinics in Riyadh,
Kingdom of Saudi Arabia. Ethics approval was obtained
from the ethics committee of the College of Medicine
Research Center at King Saud University, Riyadh, KSA.
Subjects
A total of 120 adult Saudi patients (males and females)
with controlled T2DM (known cases), aged 30 year and
above but not exceeding 70 years, were randomly
recruited for the study. Subjects were excluded if taking
mineral oil products, using antacids regularly, taking
cortisone or other steroids, diuretics, weight-loss drugs,
phenobarbital and phenytoin, having liver problems,
gallbladder disease or gastrointestinal disorders and tak-
ing daily multivitamins. Patients receiving hypoglycemic
agents and statins were allowed in the study and changes
in drug doses were noted.
All subjects were given a general questionnaire, which
includes thorough past and present medical history.
They then underwent a physical examination and
required to submit written informed consents prior to
being included in the study. All subjects were given a
six-month supply of 2000 IU Vitamin D3 tablets(Vigantoletten; Merck Pharma, Germany) to be taken
daily, after which and every 6 months they were to re-
turn to their assigned primary care center for another
examination and prescription refill.Anthropometry
All anthropometric parameters were obtained while the
subject was standing erect and barefoot. Height and
weight were determined using standardized conventional
methods. Body mass index (BMI) was calculated using
the formula: weight in kilograms (kg) divided by height
in squared meters (m²). A standardized mercurial sphyg-
momanometer was used to take the blood pressure of
each participant 30 min after complete rest.Laboratory parameters
Fasting blood samples were collected at baseline for
quantification of different metabolic parameters. This
procedure was repeated every 6 months prior to the re-
fill of the next vitamin D supplements. Fasting blood
glucose, lipid profile, albumin, phosphorous and calcium
were determined using routine laboratory procedures
(Konelab, Espoo, Finland). Serum insulin was quantified
using multiplex assay kits (LuminexW xMAPW Technol-
ogy platform) (Luminexcorp, Texas). The intra-assay
variation was 1.4–7.9% and inter-assay variation of
<21%. Minimum detectable concentration (MDC) for
insulin was 50.9 pg/ml. Parathyroid hormone (PTH) and
25-hydroxy-vitamin D were measured using enzyme-
linked immunosorbent assay (IDS Ltd., Boldon Colliery,
Tyne & Wear, UK). The inter- and intra-assay variabil-
ities were 5.8% and 3.4%, for intact PTH, and 5.3% and
4.6%, for 25-hydroxyvitamin D, respectively. All mea-
surements were performed in a DEQA- (Vitamin D Ex-
ternal Quality Assessment) participating laboratory, the
Biomarkers Research Program (BRP) of King Saud Uni-
versity, Riyadh, KSA.
Homeostasis model assessment for insulin resistance
(HOMA-IR) was calculated as fasting insulin (IU) x fast-
ing glucose (mmol/L)/22.5. HOMA-β secretion (%) was
calculated as 20 x fasting insulin (IU)/(fasting glucose—
3.5) [20]. Vitamin D deficiency was defined as serum 25-
hydroxyvitamin D level <50 nmol/L.Statistical analysis
The Statistical Package for the Social Sciences (SSPS) for
Windows version 16.5 (Chicago, Illinois) was used for
statistical evaluation of data. Variables exhibiting non-
Gaussian distribution were logarithmically transformed.
Repeated measures analysis of variance (ANOVA) was
undertaken to compare values over time. A p-value< 0
.05 was deemed significant.
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Improved vitamin D and metabolic profile after
18 months of supplementation
The general characteristics of all T2DM subjects are pre-
sented in Table 1. Vitamin D deficiency was noted in all
subjects. Despite supplementation, all subjects remained
vitamin D deficient by as much as 22% even after
18 months of therapy. None of the subjects reported
changes in their oral hypoglycemic agent, insulin and
statin dosage. Of the 120 subjects who enrolled, 92 sub-
jects (34 males and 58 females) (23.3% attrition rate)
were able to complete the entirety of the 18 month
supplementation. There was a significant improvement
in the circulating levels of 25-hydroxyvitamin D from
baseline to 6 months (32.2 ± 1.5 vs. 57.7 ± 1.4 nmol/l)
(p< 0.001), and these levels remained unchanged over
the course of the supplementation period. In parallel, a
significant improvement in the lipid profile of subjects
was observed as evidenced by a decrease in total chol-
esterol (4.8 ± 0.28 mmol/l) as compared to baseline
(5.4 ± 0.21 mmol/l) (p< 0.001), as well as LDL-cholesterolTable 1 General characteristics of all T2DM subjects according
Baseline 6 Months
N 92
M/F 34/58
DMT2 Duration (years) 7.2 ± 5.9
Insulin (N%) 18 (19.6)
Sulfonylurea (N%) 68 (73.9)
Statins (N%) 44 (47.8)
Diet (N%) 6 (6.5)
Age (years) 53.9 ± 10.2
Systolic BP (mmHg) 126.0 ± 14.1 125.3 ± 17.2
Diastolic BP (mmHg) 79.6 ± 7.3 79.0 ± 10.1
BMI (kg/m2) 32.5 ± 5.0 32.6 ± 4.9
Glucose (mmol/l) 10.7 ± 3.8 11.0 ± 4.3
T. Cholesterol (mmol/l) 5.4 ± 0.21 5.2 ± 0.25
Triglycerides (mmol/l) 1.9 ± 0.33 2.0 ± 0.32
HDL-Chol (mmol/l) 1.0 ± 0.35 1.1 ± 0.26
LDL-Chol (mmol/l) 4.3 ± 0.93 4.0 ± 0.85
Corr. Calcium (mmol/l) 2.3 ± 0.23 2.4 ± 0.17
Albumin (g/L) 43.5 ± 6.5 40.3 ± 6.6
Insulin (IU/ml) 14.0 ± 2.0 18.9 ± 2.3
PTH (pmole/l) 1.3 ± 0.39 0.96 ± 0.24
HOMA-IR 6.2 ± 1.0 8.0 ± 1.0
HOMA β-cell function 52.1 ± 9.0 72.5 ± 15.3
25-(OH) D (nmol/l) 32.2 ± 1.5 57.7 ± 1.4*
Magnesium (mmol/l) 0.69 ± 0.11 0.67 ± 0.08
Phosphorus (mmol/l) 1.17 ± 0.23 1.17 ± 0.23
Note: Data presented as mean ± SD; * denotes significance compared to baseline;(4.3 ± 0.93 vs. 3.7 ± 1.0mmol/l) (p = 0.004) after 18months.
Worthy to note was the non-significant increase in HDL-
cholesterol across time points. Other metabolic para-
meters that changed significantly were an increase of
serum calcium (p = 0.003); insulin (p< 0.001) and
HOMA-IR (p< 0.001), and HOMA-β cell function
(p = 0.002). Of note was the significant decrease in serum
albumin (p< 0.001). The rest of the parameters (blood
pressure, BMI, glucose, serum magnesium and phos-
phorus were similar.
Gender differences in metabolic improvements after
vitamin D supplementation
We examined whether there were apparent differences
in the improvement of metabolic profile in males vs.
females (Table 2). In males, there was an increase in
the circulating levels of 25-hydroxyvitamin D that was
apparent on the 6 month evaluation (30.9 ± 1.4 vs.
55.7 ± 1.3 nmol/l, p< 0.001). A significant increase was
also observed in serum calcium levels in men but not
women (p = 0.03). The improvement in metabolicto follow-up
12 Months 18 Months P value
128.4 ± 14.4 126.1 ± 8.1 0.46
79.6 ± 9.5 77.2 ± 6.2 0.27
32.8 ± 4.9 33.2 ± 5.2 0.12
11.7 ± 4.1 10.9 ± 4.4 0.21
4.9 ± 0.22* 4.8 ± 0.28* <0.001
1.9 ± 0.26 1.9 ± 0.34 0.15
1.12 ± 0.27 1.2 ± 0.37 0.38
3.7 ± 1.1* 3.7 ± 1.0* 0.004
2.5 ± 0.22 2.56 ± 0.14* 0.003
40.0 ± 4.0* 39.5 ± 4.7* <0.001
27.0 ± 1.8* 24.5 ± 2.1* <0.001
0.91 ± 0.22* 0.92 ± 0.23* 0.02
11.9 ± 1.0* 11.4 ± 1.4* <0.001
82.7 ± 9.5* 96.5 ± 15.3* 0.002
48.1 ± 1.4*# 54.7 ± 1.5* <0.001
0.66 ± 0.05 0.70 ± 0.15 0.65
1.13 ± 0.22 1.11 ± 0.23 0.16
# denotes significance compared to 6 months; P-value significant at <0.05.
Table 2 General characteristics of male and female T2DM subjects according to follow-up
MALES FEMALES
Baseline 6 Months 12 Months 18 Months P val Baseline 6 Months 12 Months 18 Months P val
N 34 58
DMT2 Duration (years) 7.3 ± 6.5 7.1 ± 5.5
Age (years) 56.6 ± 8.7 51.2 ± 10.6
Systolic BP (mmHg) 127.0 ± 15.2 125.2 ± 17.5 131.7 ± 16.2 124.9 ± 8.5 0.05 127.3 ± 13.4 125.4 ± 17.2 126.3 ± 12.9 126.7 ± 7.8 0.90
Diastolic BP (mmHg) 79.3 ± 7.4 80.4 ± 10.1 80.7 ± 8.5 76.2 ± 5.1 0.10 79.7 ± 7.3 78.0 ± 10.1 78.9 ± 10.1 77.9 ± 7.1 0.72
BMI (kg/m2) 29.0 ± 3.3 29.2 ± 3.7 29.1 ± 3.7 29.7 ± 4.3 0.41 34.2 ± 4.9 34.4 ± 4.6 34.7 ± 4.5 3.4.9 ± 4.7 0.30
Glucose (mmol/l) 10.9 ± 4.6 10.8 ± 3.8 12.8 ± 3.9 11.3 ± 5.2 0.11 10.6 ± 3.4 11.2 ± 4.6 11.2 ± 4.1 10.8 ± 3.9 0.70
T Cholesterol (mmol/l) 5.4 ± 1.2 5.5 ± 1.6 5.0 ± 1.0 4.9 ± 1.1 0.11 5.5 ± 0.84 5.3 ± 1.0 4.9 ± 0.99* 4.9 ± 1.2* <0.001
Triglycerides (mmol/l) 1.8 ± 0.31 2.1 ± 0.32 2.0 ± 0.29 1.8 ± 0.32 0.25 1.9 ± 0.35 2.0 ± 0.33 1.7 ± 0.25 1.9 ± 0.34 0.14
HDL-Chol (mmol/l) 1.4 ± 0.29 1.1 ± 0.07 1.1 ± 0.11 1.1 ± 0.12 0.10 1.0 ± 0.12 1.1 ± 0.13 1.1 ± 0.13 1.2 ± 0.17 0.16
LDL-Chol (mmol/l) 4.2 ± 1.5 4.1 ± 1.4 4.0 ± 1.9 4.1 ± 2.4 0.68 4.4 ± 0.80 4.0 ± 0.77 3.6 ± 0.90* 3.6 ± 0.77* 0.004
Corr. Calcium (mmol/l) 2.2 ± 0.22 2.4 ± 0.19 2.5 ± 0.27* 2.5 ± 0.10* 0.03 2.4 ± 0.21 2.4 ± 0.16 2.5 ± 0.19 2.5 ± 0.17 0.06
Albumin (g/L) 47.0 ± 7.9 43.9 ± 9.0 42.3 ± 3.0 42.6 ± 4.4 0.11 41.6 ± 4.5 38.3 ± 3.4* 39.4 ± 3.9* 37.7 ± 4.0* <0.001
Insulin (IU/ml) 15.2 ± 1.9 18.9 ± 2.2 24.5 ± 2.1 21.5 ± 2.1 0.23 13.0 ± 2.1 19.0 ± 2.4 28.5 ± 1.6* 22.0 ± 2.2* 0.001
PTH (pmole/l) 1.1 ± 0.32 0.88 ± 0.20 0.89 ± 0.23 0.91 ± 0.24 0.06 1.4 ± 0.44 0.99 ± 0.34 0.97 ± 0.35 0.98 ± 0.32 0.09
HOMA-IR 6.8 ± 0.86 8.2 ± 0.96 11.1 ± 0.99 12.2 ± 1.1 0.32 5.8 ± 1.0 8.2 ± 0.99 12.4 ± 0.97* 11.2 ± 1.3* 0.01
HOMA β function (%) 52.0 ± 12.9 69.5 ± 10.7 66.1 ± 8.7 85.9 ± 15.3 0.12 50.6 ± 7.8 74.4 ± 18.1 91.6 ± 9.8* 86.3 ± 15.2* 0.004
25-(OH) D (nmol/l) 30.9 ± 1.4 55.7 ± 1.3* 50.6 ± 1.3* 55.7 ± 1.2* <0.001 33.7 ± 1.6 59.7 ± 1.4* 46.7 ± 1.5* 54.9 ± 1.5* <0.001
Magnesium (mmol/l) 0.71 ± 0.19 0.7 ± 0.07 0.70 ± 0.04 0.71 ± 0.05 0.90 0.69 ± 0.08 0.65 ± 0.08 0.65 ± 0.04 0.70 ± 0.19 0.73
Phosphorus (mmol/l) 1.20 ± 0.25 1.15 ± 0.21 1.05 ± 0.22 1.04 ± 0.19* 0.009 1.15 ± 0.22 1.20 ± 0.21 1.17 ± 0.22 1.16 ± 0.25 0.52
Note: Data presented as mean ± SD; * denotes significance compared to baseline; # denotes significance compared to 6 months; P-value significant at <0.05.
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improved levels in total and LDL-cholesterol (p< 0.001
and 0.004, respectively), albumin (p< 0.001), insulin
(p< 0.001), HOMA-IR (p< 0.01) and HOMA-β cell
function (p < 0.004), as well as 25-hydroxyvitamin D
(p< 0.001). Figure 1 shows the increasing pattern of
HOMA-β secretion improvement over time despite aFigure 1 HOMA-β cell function (%) levels versus vitamin D (nmol/L) in
vitamin D3 (2000 IU) supplementation for 18 months in successive fosustained, almost significant increase in vitamin D levels
beyond 6 months.
Discussion
The findings of this study indicate that the metabolic
profile of T2DM subjects, particularly females, is signifi-
cantly improved over a period of 18 months after themale and female Saudi T2DM subjects who were on daily
llow-up visits; significance at P< 0.05.
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vitamin D correction is a promising cardio-protective
intervention in vitamin D-deficient populations. The
gender effect can be attributed indirectly to either differ-
ences in hormone secretion and/or target tissue effects
and body fat distribution, both of which can contribute
to degrees of insulin resistance, or sample size effect.
The current study adds to an increasing body of evi-
dence that vitamin D supplementation is most beneficial
not only to those who are at risk for osteoporosis and
other bone-related diseases, but also to those who are
deficient and have other extra skeletal chronic diseases,
such as diabetes T2DM and cardiovascular disease. The
available evidence, however, has been quite mixed. In a
recent study, Eftekhari and colleagues were not able to
elicit the same improved metabolic profile in an Iranian
T2DM population, which was probably due to a shorter
duration of supplementation (12 weeks) [21]. Other
studies also found no improvement of insulin sensitivity
after a high dose vitamin D intervention. This was prob-
ably partly due to the supplementation itself and/or be-
cause the subjects were apparently healthy [22,23].
Increased insulin resistance post supplementation was
observed in a cohort of middle-aged adults, and
increased insulin sensitivity in first time GDM patients
[24,25]. In the present study, the apparent health bene-
fits were observed after 6 months of supplementation,
aside from the expected increase in circulating vitamin
D levels, suggesting that sustained and prolonged sup-
plementation might be necessary to achieve desirable
metabolic effects.
Several mechanisms explain how vitamin D can theor-
etically improve metabolic functions. One mechanism
may involve direct promotion of large HDL particle for-
mation, via elevations in serum apolipoprotein A1
(ApoA1) concentrations, a process that increases reverse
cholesterol transport [26]. Furthermore, the improved
lipid profile of the DMT2 subjects can also be attributed
to lipid-lowering drugs, which were administered in al-
most half of the study population. Statins (rosuvastatin)
were shown to increase levels of 25-hydroxyvitamin D
and 1, 25 dihydroxyvitamin D in a cohort of hyperlipid-
emic patients [27]. Nevertheless, there is enough evi-
dence to support that vitamin D supplementation can
independently improve cardiovascular health secondary
to its significant associations with cardiometabolic risk
factors in both human and animal models, including
blood pressure, insulin resistance and aortic media frag-
mentation, respectively [28-30]. The increase in serum
calcium was expected, secondary to increased vitamin D
levels. This in turn results in a parallel increase in loca-
lized calcium influx in pancreatic β cells that stimulate
islet insulin secretion [31-33]. Lastly, the inverse associ-
ation to free albumin was also expected, as it is one ofthe proteins (vitamin D binding protein being the other
one) that transport 25(OH)D in the blood [34].
Several caveats should be mentioned. First, the lack of
a placebo-control group, second that the study included
only patients with T2DM, and third, the difficulty in the
verification of quality of life issues. Findings therefore
are limited to patients with T2DM, since variations in
metabolic changes differ not only by gender but also by
the presence of the disease itself [35]. The increase in
both insulin resistance and sensitivity should be inter-
preted with caution since these were computed indir-
ectly rather than directly. Nevertheless, several hard
outcomes were measured overtime, while HOMA-β
function would be difficult to elicit in a control group.
The improved HOMA-β function specifically in females
can be also explained by several confounders that were
not accounted for, such as the type of anti-diabetic drugs
taken, compliance of the patients and duration of dia-
betes. Metformin for instance, does not confer changes
in vitamin D status, while thiazolidinediones affect vita-
min D by selective agonism of peroxisome proliferator
activated receptors gamma (PPAR-γ), which are present
in muscle, liver and adipose tissue [36].
In summary, the present interventional study per-
formed in an Arab population suggests that daily
2000 IU vitamin D3 supplementation in a vitamin D de-
ficient T2DM population is associated with measurable
cardioprotective indices. Supplementation to achieve
higher levels of vitamin D remains a promising adjuvant
therapy for T2DM patients. Further studies are needed,
with the inclusion of a placebo group, to validate the
present findings.
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